Philip Morris' ILUMA Rollout: Will It Power H2 Volume Growth? (Revised)

Philip Morris International (PM) saw reaccelerated Q2 2025 adjusted in-market heated tobacco unit (HTU) sales growth of 11.4%, propelled by the global rollout of its ILUMA platform, which boosted HTU market share and is projected to sustain double-digit HTU gains, crucial for offsetting combustible declines. Despite this operational momentum, PM's stock has underperformed the industry recently and trades at a premium valuation, though 2025/2026 EPS estimates have seen slight upward revisions. Concurrently, peer Turning Point Brands reported nearly eightfold year-over-year growth in Modern Oral sales, underscoring broader industry expansion in smoke-free alternatives.

Analysis

Philip Morris International (PM) is demonstrating significant operational momentum in its transition to smoke-free products, driven by the rollout of its ILUMA heated tobacco platform. The company reported an 11.4% reacceleration in adjusted in-market sales growth for heated tobacco units (HTUs) in Q2 2025, with notable gains in Europe (+9.1%) and Japan (+7.8%). This growth is translating into tangible market share gains, with IQOS HTU share in Europe climbing 1.2 percentage points to 10.9%. Management's guidance for 12-14% smoke-free product volume growth in 2025 hinges on this ILUMA-led upgrade cycle successfully offsetting declines in the combustible segment. However, this strong fundamental performance is contrasted by the stock's recent market behavior and valuation. Shares have declined 5.7% in the past month while the industry grew 1.3%, and the stock trades at a premium forward price-to-earnings ratio of 21.17x, compared to the industry average of 15.36x. While EPS estimates for 2025 and 2026 have seen modest upward revisions, the high valuation suggests that the market has already priced in substantial growth, creating a high bar for execution. The broader competitive landscape is also intensifying, evidenced by competitor Turning Point Brands reporting nearly eightfold year-over-year growth in its Modern Oral segment.

Key Decisions for Investors

• Investors should weigh the company's strong operational execution and double-digit HTU growth against its premium valuation and recent stock underperformance, as further share price appreciation may depend on exceeding already high market expectations.
• Monitor the rollout momentum and market share progression of the ILUMA platform in the second half of 2025, as this is the primary catalyst for achieving the company's 12-14% smoke-free volume growth target.
• Consider the potential risks from intensifying competition in the broader smoke-free category, highlighted by peers like Turning Point Brands, and keep a close watch on any regulatory developments in key markets which could impact growth trajectories.